DaVita Inc. shares rise 1.28% to outperform market on down day

10 articles · Updated · MarketWatch · Apr 29

DaVita Inc. stock closed at $151.99 on Wednesday, gaining for the second straight day as major indices fell.
Trading volume reached 822,285, surpassing the 50-day average, while DaVita remained 4.66% below its 52-week high of $159.42.
Compared to peers, UnitedHealth Group rose 1.08%, Icon PLC surged 13.35%, and Quest Diagnostics dropped 2.94% during the same session.

While DaVita gained 1%, competitor Icon surged 13%. What does this volatility signal for healthcare investors?

DaVita’s value-based care unit is profitable early. Is this a new growth engine or a temporary success?

Amidst a strong outlook, could a federal antitrust probe derail DaVita’s growth trajectory?

DaVita’s stock is valued at $152, but a DCF model suggests $390. What is the market failing to see?

How will DaVita's investments in AI and home care reshape the patient experience in kidney treatment?

As DaVita expands in Latin America, is a new global rivalry with Fresenius Kidney Care heating up?